Background: The response to thiopurine treatment in inflammatory bowel disease patients differs greatly among individuals and nearly 50% of patients experience no benefit. Several factors have been implicated in determining this response, including individual genetic variation.
INTRODUCTION
Thiopurine drugs, mercaptopurine (MP) and the pro-drug azathioprine (AZA), are a widely prescribed therapy in inflammatory bowel diseases (IBD), notably in patients with corticosteroid-dependent disease. Although thiopurines have shown to be effective as steroid-sparing drugs, up to 50% of patients fail to this therapy [1, 2] . Currently AZA for 6 months to 2 years is effective for preventing disease relapse in 71% patients [3] but its withdrawal is followed by a relapse rate between 14% and 41% for the first subsequent year [4, 5] . In fact, the use of thiopurine drugs is often limited, as 30% to 50% of patients discontinue these drugs due to either side-effects or lack of clinical efficacy [2, 6] .
It is generally accepted that interindividual differences to drug therapies have a substantial heritable component. However, genetics of response to thiopurine remains poorly defined. Individual variation in thiopurine metabolism accounts for the differences in therapeutic efficacy and development of adverse reactions [7] . The thiopurine methyl transferase (TPMT) enzyme methylates MP determining the level of 6-thioguanine nucleotide (6-TGN) metabolite, responsible for the therapeutic activity of thiopurines. TPMT activity is inversely related to clinical response to AZA [8] and different genetic polymorphisms code for the level of TPMT activity [9] . To date, 30 variant alleles (TPMT*2-TPMT*28) have been characterised, and are associated with decreased enzyme activity, compared with the wild-type allele (TPMT*1) [10] . In a large Spanish cohort of patients with inflammatory diseases a proportion of 0.5% of patients with deficient activity was reported [11] . So, only a few patients may benefit from TPMT genotyping for prediction of fail in response to treatment.
Use of genetic test to identify the most effective IBD treatment for each patient at the time of first presentation would have obvious clinical benefit, and efforts were made on pharmacogenetics research [10, 12, 13] . So far, pharmacogenomic studies of the immunosuppressive thiopurine drugs were mainly focused on genes involved in thiopurine metabolism and the variants that could affect intracellular concentration of 6-TGN. Besides TPMT, inosine triphosphatase A (ITPA), aldehyde oxidase 1 (AOX1), xanthine dehydrogenase (XDH), methylenetetrahydrofolate reductase (MTHFR), xantine oxidase (XO) or glutathione-S-transferase (GST) have been investigated but their importance still remains controversial [10, 13, 14] . A limitation of this approach is that the selection of candidate genes is restricted to current knowledge about the mechanisms of drug action. More exploratory methods that systematically screen the whole genome for association with drug response represent an alternative strategy for discovering relevant genetic variation. Previously we performed the first genome-wide SNP association study of variants associated with thiopurinerelated toxicity in IBD patients [15] and recently that strategy was applied to investigate thiopurine cytotoxicity using lymphoblastoid cell lines [16] .
In the present study, we used a sample of IBD patients from the Spanish EIGA study group and ENEIDA project from GETECCU to detect genetic variation underlying individual differences in response to thiopurine treatment. A two-stage exome-wide association study was performed to identify new genes involved in the response of the IBD patients to the thiopurine treatment.
MATERIAL AND METHODS

Patients
This prospective and multicenter study included an initial cohort consisting of subjects selected from a wellcharacterized and homogeneous group of IBD patients clinically evaluated and diagnosed according to the LennardJones criteria [17] , and those who were treated with thiopurines.
167 unrelated Spanish patients with IBD were recruited in the first phase of the study (initial cohort) from the EIGA group in Galicia (Northwest of Spain). 133 patients presented response to the thiopurines therapy and 34 showed no response. For subsequent replication studies, a sample of 90 patients (30 non-responders and 60 responders) from the ENEIDA (National Study on Inflammatory Bowel Disease Genetic and Environmental Determinants, Spain) project was used.
At entry, patient's demographics and clinical history were collected ( Table 1) . In short, for all patients enrolled in the study the initial dose was 2-2.5 mg/kg/day of AZA or 1-1.5 mg/kg/day of MP and was unchanged except in those patients who experienced adverse effects that could be corrected with dose reduction. Characteristics of thiopurine therapy are described in Table 1 . Patients that were receiving concomitant immunosuppressive drugs (methotrexate, anti-TNF drugs) were not included. All the patients who developed an adverse event were also excluded from the analysis. The study was performed with the approval of the ethics committee at involved institutions. Written consent was obtained from each participant.
Definition of Responder
Treatment with AZA was considered successful (responders) if the drug could maintain steroid-free remission (defined as CDAI<150 in CD and Mayo score <3 for UC) for at least 12 months, without concomitant immunosuppressive drugs. All the patients were closely monitored by blood testing in order to screen adverse events and clinical effects. Additional information was obtained from clinical records.
DNA Samples
Peripheral blood samples were obtained from each patient and the DNA extracted using the Wizard® Genomic DNA Purification Kit (Promega, Madison, USA) or automated extraction Chemagic 100 DNA Blood Kit (Chemagen AG, Baesweiler. Germany), according to instructions from company.
Exome-Wide Analysis
In the analysis of the Galician population, the exomewide analysis was performed using the GeneChip® Human (Panels 1 & 2) 20K cSNP Kit, which contains 20,000 amino acid-changing cSNPs that are multiplexed in a single assay. It includes validated non-synonymous public SNPs that code for functional changes in more than 10,000 genes. It allows researchers to perform hypothesis-driven association studies for the direct detection of non-synonymous SNPs with links to biological pathways and gene function. The Human 20K cSNP Kit data are generated using molecular inversion probe (MIP) technology in combination with Affymetrix Universal Tag Arrays, and scanned on an GeneChip® Scanner 3000 TG System Additionally, using the genotyping technology SNaPshot ® (AB Inc., Carlsbad, USA), we evaluated the SNPs that define the most common alleles with low enzymatic activity in TPMT documented in Caucasian populations: TPMT*2, *3A, *3B and *3C (rs1800462, rs1800460, rs1142345). If patients did not carry any of these SNPs they were considered to be wild type and to express normal TPMT activity.
Quality Control of Exome-Wide Analysis
Samples and markers passed stringent quality-control standard [18] . Concerning to the SNPs those with a genotyping efficiency <80%, a Minimal Allelic Frequency (MAF) less than 1%, and deviated from Hardy-Weinberg Equilibrium (p<1.0x10-03) in controls were eliminated. With respect to samples, those with more than 10% missing SNPs or with inconsistencies between molecular and phenotypic sex were deleted. One single individual could not be genotyped due to low quantity of available DNA. The quality control was developed with Plink program, version 1.06. After quality control, 11,666 cSNPs, and 167 samples (30 cases and 137 controls) were available for the association study.
Replication Study
All cSNPs selected for replication in the ENEIDA cohort were genotyped with iPLEX assays (Sequenom, Germany).
The cSNP assays were designed with the AssayDESIGNER software (Sequenom). The detection of cSNPs was done by the analysis of primer extension products from previously amplified genomic DNA using a Sequenom chip-based matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry platform according to the manufacturer's instructions.
Statistical Analysis
The mean and standard deviation were calculated for quantitative variables (the variables that did not follow a normal distribution were defined with median, minimum, maximum and interquartile range), and qualitative variables were expressed as percentages with 95% confidence intervals.
Statistical tests were performed using the Plink software, version 1.06 [19] , R for Windows [20] and IBM SPSS Statistics 18. The assessment of population substructuring was done using the STRUCTURE software (version 2.3.1) [21] . To identify SNPs significantly associated with the reponse from the exome-wide study, we compared allelic and genotypic frequencies between cases and controls using the X2 test or, if any cell count was less than 5, by Fisher's exact test. Also, to avoid the problem of the low frequency of rare homozygotes, genotypic analysis was performed assuming a dominant model, which includes rare heterozygous and homozygous individuals and compares them with the common homozygous group. It was considered a p-value for statistical significance of 5.0x10-6, for whole exome analysis equivalent to a Bonferroni adjustment for p-value of 5.0x10-02 assuming 11,666 tests, such as those made in this analysis. Additionally, to check the possible role of some clinical and phenotypic variables, logistic regression was performed including age, sex, type of IBD and smoking (defined as present or past history of smoking) as covariates in the regression model along with the genotype for the SNP (coded as 0/1 under the dominant model). In the analysis of the replication we conducted joint analysis of data from original and replication studies using the Cochran-Mantel-Haenszel test (CMH) [22] , which calculates a probability and an odds ratio (OR) combination with the two levels considered.
RESULTS
257 individuals with IBD were analyzed in this multicenter case-control study, 167 in the initial (discovery) cohort and 90 in the replication cohort. Main characteristics of the patients are summarized in Table 1 .
Population substructure assessment revealed no significant difference between cases and controls, and therefore we did not adjust population stratification in our association analysis. Exome-Wide Analysis Results Table 2 shows the results from exome-wide analyses. The lowest p value (p= 3.57x10 -05 ) corresponds with the cSNP rs6048760 related to the "zinc finger protein 336" (ZNF336) gene located on chromosome 20, but do not pass the Bonferroni-corrected threshold. In the Table 2 , we show the top cSNPs based on the lowest p value. Among this group of cSNPs, in addition to rs6048760, the analyses of this exome-wide highlighted several cSNPs close to a p value= 1x10 -4 : rs6063377 (DDX27 gene), rs17151692 (PION gene), rs12927214 (CNGB1 gene) or rs2820289 (NAV12 gene). In addition, the analysis of TPMT yields no significant differences in response (Fisher' exact test p=0.6964, OR=1.53, 95%CI=0.38-6.10).
Replication Study Results and Combined Meta-Analysis
We first selected the top 20 SNPs that rank highest according to their minimum p-value of the exome-wide analysis. Additionally, we included the 3 SNPs defining the mutant alleles in the TPMT gene owing to their association with TPMT activity. This set of SNPs was further tested in an independent population of IBD patients (30 non-responders and 60 responders from the ENEIDA project). No significant results were found in the replication study for association to thiopurine outcome in that cohort. Table 3 shows results for those SNPs with a significant p value in the allelic joint analysis (p-CMH<0.0025, corresponding with the Bonferroni value 0.05/20). Despite the fact that, these SNPs did not achieve the significance threshold in the replica cohort, some of them showed a suggestive probability (p value <0.10) in the allelic or genotypic association test. So, after joint analysis the SNP rs17151692 (PION gene) showed a joint probability in CMH of 4.26x -06 with an OR of 4.55 (95%CI 2.28-9.10) though it had a raw probability in the replication cohort <0.10 (p value = 0.021). Additionally, a suggestive association was found with the SNP rs6521112, located in the gene ZNF673, with a joint Table 3 the next best results are reported, with other SNPs that were not significant even though close to the significance threshold.
DISCUSSION
Understanding the biological factors, affecting response to MP or AZA may be crucial to develop diagnostic tests to match individual IBD patients to the most safe and effective treatment. In this study we performed a two-stage exome wide association study in 257 subjects from a Spanish population to detect genetic variation underlying individual differences in response to treatment with thiopurine drugs.
Besides the known association of the TPMT gene alleles with TPMT enzyme activity, TPMT polymorphisms genotyping have little utility in the prediction of thiopurine response mainly because the low frequency of these variants [11] . So, Fisher' exact test showed no significant differences in response to TPMT genotypes in both datasets: p=0.6964 (OR=1.53, 95%CI=0.38-6.10) and p=1 (OR=0.87, 95%CI=0.15-5.07) for initial and replica cohorts respectively.
Whereas not statistically significant in all of the two analyzed cohorts, the direction of the observed associations were highly consistent across samples and the allelic joined analysis suggest a significant risk for lack of response to treatment in carriers of the minor alleles in two genes, PION and ZNF673.
The top statistical joint analysis result overall was rs17151692 on chromosome 7, reaching significant (CMH p-value: 4.26x -06 ) association according to our pre-specified threshold (CMH<0.0025). The associated cSNP (rs17151692) codes for a non-synonymous substitution (Val649Ile) in exon 25 of PION gene. The relatively rare (MAF: 8%) minor A allele significantly increases risk for treatment failure 4.5 times when all data is combined. The "protein pigeon homolog"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gen e&cmd=Retrieve&dopt=full_report&list_uids=54103 (PION), also known as gamma-secretase activating protein (GSAP), is a protease with numerous substrates. This protein selectively increases amyloid-beta production through a mechanism involving its interaction with both gamma-secretase and its substrate, the C-terminal fragment of beta-amyloid precursor protein [23] The "zinc finger family member 673" (ZNF673) belongs to a subgroup of zinc finger containing transcription factor protein. Functionally, the gene has been proposed to participate in regulation of transcription by zinc ion dependant nucleic acid binding [24, 25] . The common minor G allele (MAF: 35%) of the associated SNP rs6521112 shows a 2.5-fold increase in risk for non response.
None of these genes have been investigated in relation to IBD or thiopurine outcome before. The rs17151692 SNP is nonsynonymous, that can suggest a possible functional relevance, but there is little information about PION and ZNF673 genes. It is therefore difficult to speculate on how these loci may be mediating the effects of the thiopurine treatment. Nevertheless, the lack of relation does not preclude the possibility of a true finding. It is notable that imatinib, an Abl kinase inhibitor and anti-cancer drug, was shown to mediate beta-amyloid lowering activity by binding GSAP and preventing its interaction with beta-amyloid precursor protein [26] , opening a potentially novel therapeutic strategy for the treatment of Alzheimer Disease. These findings can be indicative of long range regulatory effects medi- ated by these genes, or other mechanisms that are not yet fully understood.
In a recent study, Matimba et al. [16] genotyped SNPs associated to thiopurine lymphoblastoid cell line cytotoxicity as well as thiopurine pathway gene SNPs in 589 childhood acute lymphoblastic leukemia patients and reported novel associations for several of these SNPs with clinical measures of treatment response. A direct comparison of the results is difficult by the many differences that exist between our exome-wide analyses and those by Matimba et al., but both studies could indicate that a number of genes influence thiopurine outcome at a modest level, comparable or even higher to previously identified TPMT gene.
Several strengths and limitations of our study should be recognized. The fact that we do not find significance levels in both exome-wide and replication analysis can be explained by the lack of statistical relationship between the studied variables or the insufficiency of detection power due to a limitation in sample size. Only 257 individuals coupled to approximately 11,660 cSNPs could be included in the exome-wide analysis and 90 individuals in the replication cohort, and this represents a significant limitation. However, we had 80% power to detect an OR of 9.5 for SNPs with a MAF of 0.01. This fact supports the hypothesis of the absence of a major gene effect in BMS, but rarer SNPs or haplotypes that may have large effect sizes could not be assessed in a exome-analysis analysis.
Our genotyping method was chosen to optimize exomewide coverage and statistical analysis. Association studies restricted to common coding SNPs (cSNPs) have the advantage of strongly reducing the multiple testing problem, compared with GWAS using several hundred thousand markers, while increasing the probability of testing functional SNPs. That nonsynonymous SNPs have the potential to affect the structure or function of expressed proteins. However, only a few SNPs for each specific gene were analyzed and therefore it is possible that some relevant genetic variation in the patients was missed.
CONCLUSION
In summary, although our findings require replication, the present study demonstrates the potential of exome-wide analysis to discover novel genes that potentially mediate effects of thiopurine drugs, which could eventually help to tailor treatment for individual IBD patients. 
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